Recent Investment Analysts’ Ratings Updates for Alnylam Pharmaceuticals (ALNY)

Alnylam Pharmaceuticals (NASDAQ: ALNY) recently received a number of ratings updates from brokerages and research firms:

  • 2/9/2018 – Alnylam Pharmaceuticals was given a new $151.00 price target on by analysts at Credit Suisse Group AG. They now have a “buy” rating on the stock.
  • 2/9/2018 – Alnylam Pharmaceuticals was given a new $156.00 price target on by analysts at Jefferies Group LLC. They now have a “buy” rating on the stock.
  • 2/9/2018 – Alnylam Pharmaceuticals had its price target raised by analysts at Nomura to $86.00. They now have a “sell” rating on the stock.
  • 2/9/2018 – Alnylam Pharmaceuticals had its price target lowered by analysts at BMO Capital Markets from $165.00 to $160.00. They now have an “outperform” rating on the stock.
  • 2/9/2018 – Alnylam Pharmaceuticals had its price target lowered by analysts at Morgan Stanley from $128.00 to $118.00. They now have an “equal weight” rating on the stock.
  • 1/25/2018 – Alnylam Pharmaceuticals had its price target raised by analysts at Leerink Swann from $132.00 to $135.00. They now have a “market perform” rating on the stock.
  • 1/19/2018 – Alnylam Pharmaceuticals had its “buy” rating reaffirmed by analysts at B. Riley. They now have a $205.00 price target on the stock.
  • 1/19/2018 – Alnylam Pharmaceuticals had its “buy” rating reaffirmed by analysts at Chardan Capital. They wrote, “We now raise our PT to $175, after: (1) increasing the patisiran probability of success to 97%, and (2) lowering the Alnylam WACC to 8% to reflect further RNAi therapeutics platform de-risking. We now update our Alnylam patient-based and other models to reflect recent positives, while consolidating views from recent Chardan macro research (e.g. on novel lipid-lowering therapies). (See Figures 3-7.) Notably, a near- best-case safety and efficacy profile emerged from the pivotal APOLLO trial (as discussed in our 20 September 2017 research); and, Alnylam proceeded to file patisiran in an expeditious fashion. We thus newly model a 97% probability of success (POS) for patisiran and $1.77 billion in 2030E risk-adjusted franchise sales (patisiran and follow ons). We now increase the POS of givosiran, to 80% ($540 million in 2030E sales) from 40% in our previous model, given the product’s progress ahead of our expectations.””
  • 1/8/2018 – Alnylam Pharmaceuticals had its “buy” rating reaffirmed by analysts at B. Riley. They now have a $205.00 price target on the stock, down previously from $220.00.
  • 1/7/2018 – Alnylam Pharmaceuticals had its “buy” rating reaffirmed by analysts at Piper Jaffray Companies. They now have a $182.00 price target on the stock.
  • 12/15/2017 – Alnylam Pharmaceuticals was upgraded by analysts at Goldman Sachs Group Inc from a “buy” rating to a “conviction-buy” rating.

Shares of Alnylam Pharmaceuticals, Inc. (ALNY) traded down $0.40 on Monday, hitting $115.92. 1,304,900 shares of the stock traded hands, compared to its average volume of 926,132. Alnylam Pharmaceuticals, Inc. has a 52 week low of $44.50 and a 52 week high of $147.63. The firm has a market cap of $11,550.00, a price-to-earnings ratio of -21.43 and a beta of 2.68. The company has a current ratio of 9.83, a quick ratio of 9.83 and a debt-to-equity ratio of 0.14.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its quarterly earnings results on Thursday, February 8th. The biopharmaceutical company reported ($1.48) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.38) by ($0.10). Alnylam Pharmaceuticals had a negative return on equity of 48.88% and a negative net margin of 545.95%. The business had revenue of $37.90 million for the quarter, compared to analyst estimates of $19.31 million. During the same quarter last year, the company earned ($1.32) EPS. The business’s revenue for the quarter was up 116.6% compared to the same quarter last year. research analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -5.69 EPS for the current year.

In related news, CEO John Maraganore sold 74,000 shares of the firm’s stock in a transaction on Wednesday, November 15th. The shares were sold at an average price of $126.86, for a total value of $9,387,640.00. Following the transaction, the chief executive officer now directly owns 223,710 shares in the company, valued at approximately $28,379,850.60. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, SVP Laurie Keating sold 30,000 shares of the firm’s stock in a transaction on Friday, December 1st. The shares were sold at an average price of $135.89, for a total transaction of $4,076,700.00. Following the completion of the transaction, the senior vice president now owns 41,500 shares in the company, valued at $5,639,435. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 220,409 shares of company stock worth $28,667,017. 4.30% of the stock is currently owned by company insiders.

Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs).

Receive News & Ratings for Alnylam Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply